154 related articles for article (PubMed ID: 22484722)
1. A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.
Grosso F; D'Incalci M; Cartoafa M; Nieto A; Fernández-Teruel C; Alfaro V; Lardelli P; Roy E; Gómez J; Kahatt C; Soto-Matos A; Judson I
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1557-65. PubMed ID: 22484722
[TBL] [Abstract][Full Text] [Related]
2. Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity.
Stoyianni A; Kapodistrias N; Kampletsas E; Pentheroudakis G; Pavlidis N
Tumori; 2011; 97(2):252-5. PubMed ID: 21617727
[TBL] [Abstract][Full Text] [Related]
3. Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma.
Skorupa A; Beldner M; Kraft A; Montero AJ
Cancer Biol Ther; 2007 Jul; 6(7):1015-7. PubMed ID: 17611408
[TBL] [Abstract][Full Text] [Related]
4. Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedin.
Grosso F; D'Incalci M
Tumori; 2011; 97(2):256. PubMed ID: 21617728
[No Abstract] [Full Text] [Related]
5. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.
Le Cesne A; Yovine A; Blay JY; Delaloge S; Maki RG; Misset JL; Frontelo P; Nieto A; Jiao JJ; Demetri GD
Invest New Drugs; 2012 Jun; 30(3):1193-202. PubMed ID: 21484250
[TBL] [Abstract][Full Text] [Related]
6. Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin.
Strippoli S; Lorusso V; Albano A; Guida M
BMC Complement Altern Med; 2013 Jul; 13():199. PubMed ID: 23899130
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.
Leporini C; Patanè M; Saullo F; Rende P; Gallelli L; Di Paola ED; Toscano R; Lucia M; Rossi M; De Sarro G; Russo E
BioDrugs; 2014 Dec; 28(6):499-511. PubMed ID: 25209722
[TBL] [Abstract][Full Text] [Related]
8. Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
Martin-Liberal J; Judson I
Expert Opin Drug Saf; 2013 Nov; 12(6):905-11. PubMed ID: 23937190
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.
Lebedinsky C; Gómez J; Park YC; Nieto A; Soto-Matos A; Parekh T; Alfaro V; Roy E; Lardelli P; Kahatt C
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1223-31. PubMed ID: 21416137
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution.
Fayette J; Boyle H; Chabaud S; Favier B; Engel C; Cassier P; Thiesse P; Méeus P; Sunyach MP; Vaz G; Ray-Coquard I; Ranchère D; Decouvelaere AV; Alberti L; Pérol D; Blay JY
Anticancer Drugs; 2010 Jan; 21(1):113-9. PubMed ID: 19887935
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen.
Barone A; Chi DC; Theoret MR; Chen H; He K; Kufrin D; Helms WS; Subramaniam S; Zhao H; Patel A; Goldberg KB; Keegan P; Pazdur R
Clin Cancer Res; 2017 Dec; 23(24):7448-7453. PubMed ID: 28774898
[TBL] [Abstract][Full Text] [Related]
12. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Machiels JP; Staddon A; Herremans C; Keung C; Bernard A; Phelps C; Khokhar NZ; Knoblauch R; Parekh TV; Dirix L; Sharma S
Cancer Chemother Pharmacol; 2014 Oct; 74(4):729-37. PubMed ID: 25100135
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
Gordon EM; Sankhala KK; Chawla N; Chawla SP
Adv Ther; 2016 Jul; 33(7):1055-71. PubMed ID: 27234989
[TBL] [Abstract][Full Text] [Related]
14. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD; von Mehren M; Jones RL; Hensley ML; Schuetze SM; Staddon A; Milhem M; Elias A; Ganjoo K; Tawbi H; Van Tine BA; Spira A; Dean A; Khokhar NZ; Park YC; Knoblauch RE; Parekh TV; Maki RG; Patel SR
J Clin Oncol; 2016 Mar; 34(8):786-93. PubMed ID: 26371143
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
Forouzesh B; Hidalgo M; Chu Q; Mita A; Mita M; Schwartz G; Jimeno J; Gómez J; Alfaro V; Lebedinsky C; Zintl P; Rowinsky EK
Clin Cancer Res; 2009 May; 15(10):3591-9. PubMed ID: 19417019
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
Samuels BL; Chawla S; Patel S; von Mehren M; Hamm J; Kaiser PE; Schuetze S; Li J; Aymes A; Demetri GD
Ann Oncol; 2013 Jun; 24(6):1703-9. PubMed ID: 23385197
[TBL] [Abstract][Full Text] [Related]
19. Going further in the knowledge of Yondelis®; what's new in daily clinical practice?
Blay JY
Future Oncol; 2014 Jun; 10(8 Suppl):s13-7. PubMed ID: 25048044
[TBL] [Abstract][Full Text] [Related]
20. Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment.
Fetterly GJ; Owen JS; Stuyckens K; Passarell JA; Zannikos P; Soto-Matos A; Izquierdo MA; Perez-Ruixo JJ
Cancer Chemother Pharmacol; 2008 Jun; 62(1):135-47. PubMed ID: 17922277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
